Key points from article :
LifeSpan Vision Ventures has announced an investment in Remedium Bio, a biotechnology company developing Prometheus™, a novel gene therapy platform designed to replace multiple protein injections with a single, adjustable-dose treatment. Unlike traditional protein-based therapies, Prometheus™ delivers stable and long-lasting protein expression through a subcutaneous injection, potentially improving safety and effectiveness while reducing costs.
The investment will help advance RMD-1202, Remedium’s lead candidate, toward Phase 1 clinical trials. RMD-1202 is a GLP-1 receptor agonist therapy aimed at treating metabolic disorders, showing superior weight loss, glycemic control, and insulin response compared to daily protein injections. The platform’s flexibility allows for the development of additional treatments across musculoskeletal, immunology, and neurology disorders.
Andrew Worden, Founding Partner at LifeSpan Vision Ventures, highlighted the potential of Remedium’s technology to address age-related diseases, aligning with the firm’s mission to extend healthspan. Remedium’s CEO, Frank Luppino, emphasized the groundbreaking potential of Prometheus™ in genetic medicine, welcoming LifeSpan as an ideal partner to support the company’s next phase of growth.
